About Douglas Ross, MD
Dr. Ross graduated from Harvard Medical School in 1977, completed his residency and fellowship training at the Massachusetts General Hospital, and has been on staff since 1983. He is Co-Director of Thyroid Associates at Massachusetts General Hospital. His endocrine practice concentrates on thyroid disorders, with an emphasis on hyperthyroidism, thyroid cancer and thyroid nodules. Procedures include radioiodine treatment for hyperthyroidism and thyroid cancer, and ultrasound-guided fine needle aspiration of thyroid nodules.
Departments, Centers, & Programs:
Clinical Interests:
- Endocrinology
- Thyroid disorders
Treats:
- Adult
Locations
Mass General Endocrinology: Thyroid Associates
55 Fruit St.
Wang Ambulatory Care Center
Suite 730
Boston, MA 02114
Phone: 617-726-3872
Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Health Care
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Ross has recently done outcome research for patients with micropapillary thyroid cancer using the National Thyroid Cancer Treatment Cooperative Study Group.
Publications
-
Dr. Ross is Thyroid Editor of UpToDate, and author of over 40 UpToDate topics.
He also has numerous publications in peer-reviewed journals, several of which involve outcome analysis for the National Thyroid Cancer Treatment Cooperative Study Group.